Home/Pipeline/Anti-infective Candidate(s)

Anti-infective Candidate(s)

Bacterial Infections

Phase II / Phase IIIActive

Key Facts

Indication

Bacterial Infections

Phase

Phase II / Phase III

Status

Active

Company

China Resources Pharmaceutical Group

About China Resources Pharmaceutical Group

CR Pharma's mission is to serve as a foundational pillar of China's national healthcare system through its integrated pharmaceutical platform. Its key achievements include establishing one of the country's largest distribution networks, a significant manufacturing base, and an extensive retail pharmacy chain under the CRCare brand. The company's strategy is centered on vertical integration, leveraging its state-backed position to consolidate market share, control supply chains, and commercialize products from its R&D pipeline across key therapeutic areas. This approach aims to secure sustainable growth amid government-led volume-based procurement and an aging population.

View full company profile

Therapeutic Areas

Cardiovascular Anti-infectives Metabolic Diseases Oncology Supportive Care Autoimmune Disorders

Other Bacterial Infections Drugs

Drug	Company	Phase	Status
Generic Portfolio Expansion - Anti-infectives	Alkaloid AD Skopje	Regulatory Submission	Active
Vibativ® (telavancin)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
Penicillin V API	Biotika	Commercial	Active
Sterile Injectable Antibiotics Portfolio	Steripharma	Approved	Active
Oral Antibiotic	Dawah Pharmaceuticals	ANDA Filed/Pre-approval	Active
XAB05/XAB06	Xenothera	Preclinical	Active
Antibacterial Program	Prosetta Biosciences	Preclinical	Active
Novel Antibiotic Class 1	ArrePath	Pre-clinical	Active
Novel Antibiotic Class 2	ArrePath	Pre-clinical	Active
Amoxicillin/AmoxiClav Generics	Puren Pharmaceuticals	Approved	Active
Ready-to-Use Antibiotics in Bags	Galenica Senese	Commercial	Active
Lasvic (Lascufloxacin)	KYORIN Pharmaceutical	Marketed	Active